As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
ORGANIZATION
JPMA to Call on Its Member Companies to Ask Lecturers at Seminars Sponsored by Them for Their Permission to Disclose COI-Related Information
At a meeting of its board of directors in Osaka on April 18, the Japan Pharmaceutical Manufacturers Association (JPMA) reported on its response to requests from the Japan Medical Association (JMA) and the Japanese Association of Medical Sciences (JAMS) regarding…
To read the full story
ORGANIZATION
- PhRMA Chief Warns Japan Is Losing Its Appeal, Urges End to On-Patent Price Cuts
November 19, 2025
- Policy Veterans’ Group Calls for Value-Based Pricing for Regenerative Medicine
November 14, 2025
- JPMA Exec Urges Immediate Action on Inflation Pressures as Budget Talks Loom
November 14, 2025
- JPMA’s Yoshida Urges Pro-Innovation Rules to Boost Japan’s Appeal amid MFN Fears
November 11, 2025
- Labor Union Calls for Uniform Hike in Drug Prices, Lawmakers Urge Overhaul
October 29, 2025
Japan is set to tighten reimbursement rules for regenerative medicine products granted conditional, time-limited approval, with Central Social Insurance Medical…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…